(CPRX) Catalyst Pharmaceuticals - Ratings and Ratios
Firdapse, Fycompa, Ruzurgi, Agamree
CPRX EPS (Earnings per Share)
CPRX Revenue
Description: CPRX Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company specializing in rare disease treatments in the US. The companys product portfolio includes Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS), Fycompa for focal onset and tonic-clonic seizures, Ruzurgi for pediatric LEMS, and AGAMREE, a corticosteroid for Duchenne Muscular Dystrophy.
From a business perspective, Catalyst Pharmaceuticals has established strategic partnerships, including license agreements with BioMarin Pharmaceutical Inc. and a collaboration with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. This diversification of partnerships and products indicates a robust business model. Key Performance Indicators (KPIs) to monitor include revenue growth from its existing product portfolio, particularly from Firdapse and Ruzurgi, as well as the successful commercialization of AGAMREE.
The companys focus on rare diseases positions it in a niche market with potentially less competition compared to broader therapeutic areas. Its ability to effectively commercialize and market its products will be crucial. Other important KPIs include the companys research and development pipeline, particularly any new drug candidates or expanded indications for existing drugs, which could drive future growth. Additionally, the companys ability to manage its expenses and maintain a healthy balance sheet will be important, given the high costs associated with drug development and commercialization.
From a financial perspective, Catalyst Pharmaceuticals market capitalization stands at approximately $2.576 billion, with a forward P/E ratio of 11.39, indicating the markets expectations for future earnings growth. The companys Return on Equity (RoE) of 28.28% suggests efficient use of shareholder equity. Monitoring these financial metrics, along with the companys cash flow and debt levels, will be essential in assessing its financial health and ability to fund future initiatives.
CPRX Stock Overview
| Market Cap in USD | 2,551m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2006-11-08 |
CPRX Stock Ratings
| Growth Rating | 29.0% |
| Fundamental | 91.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -15.9% |
| Analyst Rating | 4.86 of 5 |
CPRX Dividends
Currently no dividends paidCPRX Growth Ratios
| Growth Correlation 3m | -28.1% |
| Growth Correlation 12m | -37.1% |
| Growth Correlation 5y | 92.6% |
| CAGR 5y | 15.46% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.34 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.77 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | -16.46 |
| Beta | 0.788 |
| Volatility | 40.04% |
| Current Volume | 1031.4k |
| Average Volume 20d | 1257k |
| Stop Loss | 19.6 (-4.6%) |
| Signal | 0.03 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (208.7m TTM) > 0 and > 6% of Revenue (6% = 33.5m TTM) |
| FCFTA 0.28 (>2.0%) and ΔFCFTA 16.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 115.6% (prev 87.95%; Δ 27.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.28 (>3.0%) and CFO 275.1m > Net Income 208.7m (YES >=105%, WARN >=100%) |
| Net Debt (-649.8m) to EBITDA (274.8m) ratio: -2.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (127.5m) change vs 12m ago 2.32% (target <= -2.0% for YES) |
| Gross Margin 84.10% (prev 82.44%; Δ 1.66pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 66.56% (prev 61.51%; Δ 5.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.55 (EBITDA TTM 274.8m / Interest Expense TTM -76.5m) >= 6 (WARN >= 3) |
Altman Z'' 10.82
| (A) 0.66 = (Total Current Assets 758.7m - Total Current Liabilities 113.0m) / Total Assets 971.9m |
| (B) 0.41 = Retained Earnings (Balance) 394.0m / Total Assets 971.9m |
| (C) 0.23 = EBIT TTM 195.4m / Avg Total Assets 839.1m |
| (D) 3.40 = Book Value of Equity 394.2m / Total Liabilities 115.9m |
| Total Rating: 10.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 91.86
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 14.45% = 5.0 |
| 3. FCF Margin 49.19% = 7.50 |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -2.36 = 2.50 |
| 6. ROIC - WACC (= 10.43)% = 12.50 |
| 7. RoE 27.47% = 2.29 |
| 8. Rev. Trend 93.60% = 7.02 |
| 9. EPS Trend 31.12% = 1.56 |
What is the price of CPRX shares?
Over the past week, the price has changed by +0.93%, over one month by +2.65%, over three months by -4.20% and over the past year by -2.88%.
Is Catalyst Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CPRX is around 20.42 USD . This means that CPRX is currently overvalued and has a potential downside of -0.63%.
Is CPRX a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.3 | 66.9% |
| Analysts Target Price | 34.3 | 66.9% |
| ValueRay Target Price | 22.9 | 11.2% |
Last update: 2025-10-04 03:49
CPRX Fundamental Data Overview
P/E Trailing = 12.6303
P/E Forward = 10.0
P/S = 4.5669
P/B = 2.9896
Beta = 0.788
Revenue TTM = 558.5m USD
EBIT TTM = 195.4m USD
EBITDA TTM = 274.8m USD
Long Term Debt = 2.99m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 419.0k USD (from shortTermDebt, last quarter)
Debt = 2.99m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -649.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.90b USD (2.55b + Debt 2.99m - CCE 652.8m)
Interest Coverage Ratio = -2.55 (Ebit TTM 195.4m / Interest Expense TTM -76.5m)
FCF Yield = 14.45% (FCF TTM 274.7m / Enterprise Value 1.90b)
FCF Margin = 49.19% (FCF TTM 274.7m / Revenue TTM 558.5m)
Net Margin = 37.36% (Net Income TTM 208.7m / Revenue TTM 558.5m)
Gross Margin = 84.10% ((Revenue TTM 558.5m - Cost of Revenue TTM 88.8m) / Revenue TTM)
Gross Margin QoQ = 79.56% (prev 87.33%)
Tobins Q-Ratio = 1.96 (Enterprise Value 1.90b / Total Assets 971.9m)
Interest Expense / Debt = 56.97% (Interest Expense 1.70m / Debt 2.99m)
Taxrate = 24.80% (17.2m / 69.3m)
NOPAT = 147.0m (EBIT 195.4m * (1 - 24.80%))
Current Ratio = 6.71 (Total Current Assets 758.7m / Total Current Liabilities 113.0m)
Debt / Equity = 0.00 (Debt 2.99m / totalStockholderEquity, last quarter 856.0m)
Debt / EBITDA = -2.36 (Net Debt -649.8m / EBITDA 274.8m)
Debt / FCF = -2.37 (Net Debt -649.8m / FCF TTM 274.7m)
Total Stockholder Equity = 759.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.47% (Net Income 208.7m / Total Assets 971.9m)
RoE = 27.47% (Net Income TTM 208.7m / Total Stockholder Equity 759.7m)
RoCE = 25.62% (EBIT 195.4m / Capital Employed (Equity 759.7m + L.T.Debt 2.99m))
RoIC = 19.34% (NOPAT 147.0m / Invested Capital 759.7m)
WACC = 8.91% (E(2.55b)/V(2.55b) * Re(8.92%) + (debt cost/tax rate unavailable))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.89%
[DCF Debug] Terminal Value 78.65% ; FCFE base≈197.3m ; Y1≈243.4m ; Y5≈415.3m
Fair Price DCF = 48.97 (DCF Value 5.99b / Shares Outstanding 122.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 31.12 | EPS CAGR: -17.25% | SUE: -2.56 | # QB: 0
Revenue Correlation: 93.60 | Revenue CAGR: 40.76% | SUE: 1.48 | # QB: 4
Additional Sources for CPRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle